Publications by authors named "Darya Astafeva"

Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder that affects a significant proportion of the world's population, particularly children and adolescents. The sensory processing issues can be an evidence-based target for therapeutic/corrective interventions by controlling the intensity and targeted replacement of maladaptive sensory stimuli with neutral stimuli using virtual reality or augmented reality.

Subjects And Methods: We searched for articles on Pubmed.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates employee burnout stemming from prolonged workplace stress and aims to develop techniques to address it, specifically using a virtual reality (VR) and biofeedback intervention called ReViSide.
  • In a randomized controlled trial with 140 adult participants experiencing emotional burnout, one group will use the ReViSide technology while the control group receives traditional psychocorrection, measuring outcomes like emotional burnout and mental health symptoms.
  • The hypothesis is that participants using VR will show more significant improvements in burnout levels, including emotional exhaustion and personal accomplishment, along with potential changes in brain activity linked to lower distress levels.
View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) is a major global health concern with limited treatment options, leading researchers to investigate non-invasive therapies like repetitive transcranial magnetic stimulation (rTMS) to improve cognitive function in patients.
  • A systematic review and meta-analysis of 22 studies found that high-frequency rTMS, especially targeting the dorsolateral prefrontal cortex, significantly enhanced cognitive abilities in AD patients with a moderate effect size.
  • While the findings are promising, they also revealed substantial variability among studies and potential publication bias, indicating the need for further investigation to optimize rTMS treatment parameters.
View Article and Find Full Text PDF

Background: The prevalence of depressive disorders in the general population increased significantly during the COVID-19 pandemic. The aim of this study is to examine the relationship between history of anxiety and depressive disorders and COVID-19 outcome, hospitalization and severity of anxiety and depression, and whether such relationships are explicable by direct impact of the disease.

Subjects And Methods: We conducted a questionnaire survey among 98 inpatients in the Department of Infectious Diseases of the Clinics of Samara State Medical University.

View Article and Find Full Text PDF

Introduction: Schizophrenia is a severe mental illness causing significant impairment in personal, family, social, educational, occupational, and other important areas of life. While there is no widely accepted endophenotype, peripheral blood cells may serve as an accessible model of intracellular changes in schizophrenia.

Methods: We reviewed the literature on the query "peripheral blood mononuclear cells AND schizophrenia" in Medline (Pubmed), selecting studies that searched for specific biomarkers of schizophrenia.

View Article and Find Full Text PDF

Background: Mixed affective states (MS) are often misdiagnosed by the clinicians and lead to the inappropriate treatment strategies contributing to the severe forms, poor outcome with higher rates of comorbid conditions and worse remission quality in affective and bipolar disorders, as well as to a decreased psychosocial functioning of these patients. The development of reliable tools for the MS assessments or so called the phenomenon of mixity in affective disorders, is still an unmet need of psychiatric research and clinical practice. In this paper, we present PC program "Multilingual IBM-PC on-line calculator for early diagnosis of the mixed affective states" based on the Giuseppe Tavormina Mixed States Rating Scale (G.

View Article and Find Full Text PDF

Background: Depression is a common mental illness, with around 280 million people suffering from depression worldwide. At present, the main way to quantify the severity of depression is through psychometric scales, which entail subjectivity on the part of both patient and clinician. In the last few years, deep (machine) learning is emerging as a more objective approach for measuring depression severity.

View Article and Find Full Text PDF

Background: Depressive disorders are characterized by fluctuating symptom severity, and developing an individual prognostic model for relapse is crucial for effective prevention. Chronobiological factors are poorly understood in this context.

Methods: A systematic search was conducted to identify articles related to the prognosis of depression recurrence based on chronobiological factors.

View Article and Find Full Text PDF

Background: Electroconvulsive therapy (ECT) is one of the most effective treatments for depressive disorders. However, ECT has a number of limitations, such as significant side effects in the neurocognitive domain and the requirement for general anesthesia. Transcranial magnetic stimulation (TMS) is an intervention that applies electric stimulation to the brain without causing convulsions, thus representing an attractive alternative to ECT.

View Article and Find Full Text PDF

Background: Depression is ranked by the World Health Organization as the single largest contributor to global disability. The shortage of health care resources, conditions of social distancing during the present pandemic, and the continuing need of patients with subclinical depression and in remission for supportive therapies, all together motivate a search for new approaches to deliver appropriate and timeous treatment for depression.

Subjects And Methods: We conducted a systematic literature search of meta-analyses and systematic reviews on the topic of mobile apps for the treatment of depression using the Medline (Pubmed) database during the period ending March 30th, 2022.

View Article and Find Full Text PDF

Background: Quarantine measures with self-isolation of varying duration have been significant psychosocial stressors in the context of the COVID-19 pandemic. The serotonin selective reuptake inhibitor fluvoxamine has been considered as a prophylaxis against depression in early COVID-19 patients, with additional benefits apparently arising from its antiviral activity. In this narrative review, we draw attention to the body of evidence showing efficacy of fluvoxamine in protecting against depressive disorders in COVID-19 patients, while also attenuating the severity of COVID-19 disease, with a notable reduction in the need for intubation and lower mortality.

View Article and Find Full Text PDF